Saltzstein, D. R., Moul, J. W., de la Motte, S., McLane, J. A., Osborne, D. W., Yang, A., & Concepcion, R. S. (2015). Randomized head-to-head prospective study of pharmacokinetic and pharmacodynamic properties of leuprolide acetate formulations: 7.5 mg single depot subcutaneous vs 7.5 mg intramuscular microsphere. In Journal of Clinical Oncology (Vol. 33, pp. e16048–e16048). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2015.33.15_suppl.e16048

Saltzstein, Daniel R., Judd W. Moul, Stephan de la Motte, John A. McLane, David W. Osborne, Alex Yang, and Raoul S. Concepcion. “Randomized head-to-head prospective study of pharmacokinetic and pharmacodynamic properties of leuprolide acetate formulations: 7.5 mg single depot subcutaneous vs 7.5 mg intramuscular microsphere.” In Journal of Clinical Oncology, 33:e16048–e16048. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.e16048.

Saltzstein DR, Moul JW, de la Motte S, McLane JA, Osborne DW, Yang A, et al. Randomized head-to-head prospective study of pharmacokinetic and pharmacodynamic properties of leuprolide acetate formulations: 7.5 mg single depot subcutaneous vs 7.5 mg intramuscular microsphere. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. e16048–e16048.

Saltzstein, Daniel R., et al. “Randomized head-to-head prospective study of pharmacokinetic and pharmacodynamic properties of leuprolide acetate formulations: 7.5 mg single depot subcutaneous vs 7.5 mg intramuscular microsphere.” Journal of Clinical Oncology, vol. 33, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2015, pp. e16048–e16048. Crossref, doi:10.1200/jco.2015.33.15_suppl.e16048.

Saltzstein DR, Moul JW, de la Motte S, McLane JA, Osborne DW, Yang A, Concepcion RS. Randomized head-to-head prospective study of pharmacokinetic and pharmacodynamic properties of leuprolide acetate formulations: 7.5 mg single depot subcutaneous vs 7.5 mg intramuscular microsphere. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. e16048–e16048.